Stock UDJ APPLIED DNA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Applied DNA Sciences, Inc. BOERSE MUENCHEN

Equities

UDJ

US03815U4094

Medical Equipment, Supplies & Distribution

Market Closed - BOERSE MUENCHEN
Other stock markets
 15:43:46 2024-07-01 EDT 		5-day change 1st Jan Change
0.51 EUR +23.19% Intraday chart for Applied DNA Sciences, Inc. -0.48% -96.49%
06-20 Applied DNA Sciences, Inc. and Alphazyme LLC Conclude Linea (TM) RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea (TM) IVT Platform Economics CI
06-18 Applied DNA Partners With GenXys For Pharmacogenetic Testing MT

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 10.73 39.75 40.35 14.56 16.53 5.567 -
Enterprise Value (EV) 1 10.73 39.75 40.35 14.56 16.53 5.567 5.567
P/E ratio -0.92 x -2.33 x -2.6 x -1.22 x -1.59 x -0.1 x -0.57 x
Yield - - - - - - -
Capitalization / Revenue 1.99 x 20.6 x 4.47 x 0.8 x 1.24 x 1.24 x 0.82 x
EV / Revenue 1.99 x 20.6 x 4.47 x 0.8 x 1.24 x 1.24 x 0.82 x
EV / EBITDA - - - - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 60 257 374 644 683 10,215 -
Reference price 2 178.8 154.6 107.8 22.60 24.20 0.5450 0.5450
Announcement Date 19-12-12 20-12-17 21-12-09 22-12-14 23-12-07 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5.389 1.932 9.028 18.17 13.37 4.498 6.763
EBITDA - - - - - - -
EBIT 1 -9.124 -12.54 -13.11 -13.97 -10.95 -14.29 -13.42
Operating Margin -169.31% -648.98% -145.26% -76.89% -81.94% -317.76% -198.39%
Earnings before Tax (EBT) 1 -8.617 -13.03 -14.28 -8.27 -10.02 -12.76 -13.95
Net income 1 -8.933 -13.03 -14.29 -8.378 -9.947 -12.7 -13.42
Net margin -165.76% -674.61% -158.25% -46.11% -74.41% -282.24% -198.39%
EPS 2 -193.8 -66.40 -41.40 -18.60 -15.20 -5.320 -0.9500
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 19-12-12 20-12-17 21-12-09 22-12-14 23-12-07 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 4.166 6.147 4.296 3.559 5.263 4.408 2.917 0.7797 0.8912 0.9296 1.079 1.598 1.2 1.4 1.6
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -4.633 -1.994 -2.838 -4.369 -1.219 -2.704 -2.859 -4.171 -3.789 -3.618 -3.568 -3.319 - - -
Operating Margin -111.22% -32.44% -66.05% -122.76% -23.16% -61.35% -98% -534.9% -425.18% -389.16% -330.63% -207.7% - - -
Earnings before Tax (EBT) 1 -4.721 -1.76 -1.125 -0.6646 -3.844 0.5512 -3.114 -3.616 -1.13 -4.494 -3.569 -3.563 - - -
Net income 1 -4.722 -1.869 -1.124 -0.6632 -3.843 0.5883 -3.1 -3.592 -1.105 -4.626 -3.568 -3.319 - - -
Net margin -113.35% -30.4% -26.17% -18.63% -73.03% 13.35% -106.25% -460.7% -124.01% -497.6% -330.63% -207.7% - - -
EPS 2 -12.60 -4.600 -2.600 0.2000 -6.000 1.000 -4.800 -5.200 -1.800 -5.310 -0.4950 -0.3250 -0.3500 -0.2300 -0.1700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 22-02-10 22-05-12 22-08-11 22-12-14 23-02-09 23-05-11 23-08-10 23-12-07 24-02-08 24-05-10 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - 1.06 - - - - -
Capex / Sales - 55.07% - - - - -
Announcement Date 19-12-12 20-12-17 21-12-09 22-12-14 23-12-07 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Applied DNA Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.545 USD
Average target price
30 USD
Spread / Average Target
+5,404.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOMÉRIEUX Stock bioMérieux
-10.83% 11.24B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-15.14% 7.29B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+29.03% 5.57B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+0.04% 5.31B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-19.93% 3.68B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+7.75% 2.58B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-66.78% 2.33B
VITROLIFE AB Stock Vitrolife AB
-11.20% 2.23B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+25.24% 2.21B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. APDN Stock
  4. UDJ Stock
  5. Financials Applied DNA Sciences, Inc.